Opinion|Videos|May 5, 2025
Results of Lp(a) Testing to Modify Risk Assessment and Optimize Treatment
Experts discuss how knowledge of lipoprotein(a) (Lp[a]) levels can empower patients in managing atherosclerotic cardiovascular disease (ASCVD) risk factors, how providers can collaborate with patients on Lp(a) testing and risk management, the potential population-level value of improved ASCVD risk assessment, and how the National Lipid Association’s (NLA) recommendation for one-time Lp(a) testing may benefit health systems.
Advertisement
Video content above is prompted by the following:
- How might knowledge of Lp(a) levels empower patients in their management of ASCVD risk factors?
- How might providers partner with their patients with respect to Lp(a) testing and ASCVD risk management?
- What value might improved ASCVD risk assessment and risk factor management offer on a population level, such as to a health care system?
- The NLA recommends Lp(a) testing only once in a patient’s lifetime. How, if at all, might this frequency benefit health systems?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
2
Social Factors May Match, Outpace Genetic Risk in Disease Prediction
3
First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention
4
Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk
5